liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A triple-transgenic immunotolerant mouse model.
AstraZeneca, Safety Assessment, Södertälje, Sweden.
AstraZeneca, Discovery Sciences, Mölndal, Sweden.
AstraZeneca, Safety Assessment, Södertälje, Sweden.
AstraZeneca, Innovative Medicines, Mölndal, Sweden.
Show others and affiliations
2013 (English)In: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 102, no 3, 1116-24 p.Article in journal (Refereed) Published
Abstract [en]

Avoiding unwanted immunogenicity is of key importance in the development of therapeutic drug proteins. Animal models are of less predictive value because most of the drug proteins are recognized as foreign proteins. However, different methods have been developed to obtain immunotolerant animal models. So far, the immunotolerant animal models have been developed to assess one protein at a time and are not suitable for the assessment of combination products. Our aim was to develop an animal model for evaluating the impact of manufacturing and formulation changes on immunogenicity, suitable for both single protein and combination products. We constructed two lines of transgenic mice expressing the three human coagulation factors, II, VII, and X, by inserting a single vector containing the three coagulation factors encoding sequences separated by insulator sequences derived from the chicken beta-globin locus into the mouse genome. Immunization of transgenic mice from the two lines and their wild-type littermates showed that transgenic mice from both lines were immunotolerant to the expressed human coagulation factors. We conclude that transgenic mice immunotolerant to multiple proteins can be obtained, and that these mice are potentially useful as animal models in the assessment of immunogenicity in response to manufacturing changes.

Place, publisher, year, edition, pages
2013. Vol. 102, no 3, 1116-24 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-90439DOI: 10.1002/jps.23447PubMedID: 23316010OAI: diva2:613318
Available from: 2013-03-27 Created: 2013-03-27 Last updated: 2013-03-27

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
In the same journal
Journal of Pharmaceutical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 35 hits
ReferencesLink to record
Permanent link

Direct link